Clinical Trial

Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer

Study acronym: INTERVAL
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical trial is a single-arm, non-randomized, prospective phase II study. The study aims to evaluate if the maintenance immunotherapy with cemiplimab in patients with AdrenoCortical Carcinoma (ACC), who obtained disease response or stabilization after first-line chemotherapy, may delay/prevent disease progression. The study will be conducted at ASST Spedali Civili Hospital, Brescia - Italy.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-24.
Status change: Not Yet Recruiting → Recruiting 2025-10-01
Trial Details
NCT Number NCT07085572
Lead Sponsor Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Conditions Adrenal Cortical Carcinoma
Enrollment 31 participants
Start Date 2025-09-18
Primary Completion 2028-07 (estimated)
Study Completion 2028-07 (estimated)
Updated on ClinicalTrials.gov 2025-10-06